

FDA-Approved Adalimumab Biosimilars (U.S.)

Sources: FDA-approved Prescribing Information (Drugs@FDA / accessdata.fda.gov labels) for indications; manufacturer product websites for product pages.

Product (brand)	Nonproprietary name	FDA-approved indications (U.S.)	Main website
ABRILADA	adalimumab-afzb	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://www.abrilada.com/
AMJEVITA	adalimumab-atto	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://www.amjevita.com/
CYLTEZO	adalimumab-adbm	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://patient.boehringer-ingelheim.com/us/products/cyltezo/
HADLIMA	adalimumab-bwwd	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://www.hadlima.com/
HULIO	adalimumab-fkjp	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://adalimumabfkjp.com/
HYRIMOZ	adalimumab-adaz	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://www.hyrimoz.com/
IDACIO	adalimumab-aacf	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and pediatric ≥ 6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://www.kabicare.us/patient/program/adalimumab-aacf/
SIMLANDI	adalimumab-ryvk	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥ 2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn's disease (adults and	https://www.simlandi.com/

		pediatric ≥6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	
YUFLYMA	adalimumab-aaty	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn’s disease (adults and pediatric ≥6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://celltrionusa.com/products/yuflyma/
YUSIMRY	adalimumab-aqvh	Rheumatoid arthritis (adults); polyarticular juvenile idiopathic arthritis (≥2 years); psoriatic arthritis (adults); ankylosing spondylitis (adults); Crohn’s disease (adults and pediatric ≥6 years); ulcerative colitis (adults); plaque psoriasis (adults); hidradenitis suppurativa (adults); uveitis (adults).	https://www.yusimry.com/

Note: Some adalimumab biosimilars may have fewer pediatric indications than the reference product, HUMIRA. Always confirm current indications in the latest FDA-approved Prescribing Information.